The energy market as well as political have changed strongly in recent years. In many countries around the world, the cards on the energy mix are being reshuffled. Lars Jaeger writes in an essay for finews.first.
This article is published on finews.first, a forum for authors specialized in economic and financial topics.
The latest example is China, where President Xi Jinping announced a few days ago that his country aims to be CO2-neutral by 2060. Political decision-makers seem to have finally started on their mission to stop climate change. But is enough when politicians pay lip service?
What about our individual responsibilities for greenhouse gas emissions? What have we personally done to curb those? Many residents of industrialized countries still drive around in large cars as a matter of course, eat large quantities of meat, eat avocados from Thailand and wear T-shirts from Bangladesh. Even the corona crisis has done little to change us from wanting to take airplanes not only for our summer vacations but increasingly also for our spring and fall vacation.
Animal husbandry accounts for a particularly large proportion of the emissions
A significant amount of greenhouse gases emission is also caused by our food consumption. What we eat is cultivated, harvested, transported, stored, processed, before it finally ends up on the market and is then consumed by us, again after storage, cooling, and preparation.
Animal husbandry accounts for a particularly large proportion of the emissions. According to the Food and Agriculture Organization of the United Nations (FAO) the keeping and processing of animals account for almost 15 percent of greenhouse gas emissions worldwide. Estimates for total food production go up to 30 percent.
To produce one kilogram of beef (approx. 2,500 kcal nutritional value) the greenhouse effective equivalent of approx. 13 kilograms of CO2 is emitted, one kilo of butter (approx. 7,000 kcal nutritional value) even comes to 24 kilograms of CO2, one kilo of lamb (approx. 3,000 kcal nutritional value) to no less than 39 kg CO2, cheese (approx. 3,000 kcal nutritional value) to an average of 8.5 kilograms of CO2 per kilo. For potatoes (approx. 860 kcal nutritional value) this value stands at just 0.4 kilograms of CO2, and the production of one kilo of fresh vegetables (approx. 400 kcal nutritional value) produces on average only 0.15 kilo CO2. Vegetables, therefore, have the best CO2 balance among the basic foodstuffs.
Transportation and packaging of the finished food products play a rather minor role in the environment
Here, methods of genetic engineering, even if they are controversial in Europe, could bring further improvements. For example, there is genetically modified rice, the production of which emits fewer greenhouse gases and which at the same time yields more. The prerequisite for this is that behind these methods stands not only the greed of companies for profit, but that they are also proven by nutritional scientists to be perfectly beneficial to our health and by environmental experts to be not harmful to the biosphere.
Transportation and packaging of the finished food products play a rather minor role in the environment (as long as they are not transported by air). Relying on regional products alone only improves the food footprint by about 4 percent (some products can even be produced overseas at lower CO2 emissions). It is more important to pay attention to seasonal foods: Apples that are stored for months in cold stores are far from being as good as fresh apples in terms of their climate balance. After six months, the energy required for cooling amounts to about 22 percent of the total energy input.
According to the WWF, the CO2 footprint of a Central Europeans diet is reduced by around 25 percent if he or she switches to a vegetarian diet. With a vegan diet, it is even 40 percent. No wonder that the Intergovernmental Panel on Climate Change (IPCC) in its Special Report on Climate Change and Land Systems of August 2019 calls for a radical change in human meat consumption. In order to feed the growing world population, we need further improved methods of food production. We simply can no longer afford to keep animals for 10 billion people.
Will we there have to do without our steak or chops in the future?
In addition, it has been well-known for a long time that meat consumption, in particular that of processed meat, is not necessarily health-promoting. It significantly increases the risk of developing colon cancer (because of the proliferation of potentially aggressive bacteria in the microbiome, the bacterial intestinal flora, which causes inflammation and cells to mutate), as well as pancreatic and prostate cancer. Further consequences of heavy meat-eating are diabetes, cardiovascular diseases, kidney failure, chronic inflammation, arthrosis and rheumatism, doctors, therefore, advise reduced meat consumption.
Will we there have to do without our steak or chops in the future? No, because also in food production we will experience dramatic technological changes. They will enable us to eat healthier and more ecological food which will at the same time be tastier than what we eat today.
The production of artificial meat in the laboratory reduces greenhouse gas emissions by up to 95 percent
Food is really just a combination of protein, fat and carbohydrates plus vitamins and trace elements. These can also be put together technically with suitable processes, and this even more efficient and nutritionally more valuable than nature does. In addition, its creation in sterile cell cultures is much more suitable for industrial meat production, because it is easier to control pathogens and toxins. In addition, the time-consuming and appetizing removal of offal, hair and bones is no longer necessary. The fat content of the meat can also be controlled. And last but not least: The production of artificial meat in the laboratory reduces greenhouse gas emissions by up to 95 percent.
As early as 2013 scientists at Maastricht University produced an artificial meatball. They took muscle stem cells from cattle, mixed those with nutrients, salts, pH buffers and growth factors and left them to reproduce. The cells became cell strands, about 20,000 of which were needed for a 140-gram meatball. Almost like meat, not quite as juicy, but the consistency is perfect, test eaters commented. The effort for this prototype was immense, however, the meatball cost 250,000 euros.
Seven years later, in-vitro meat is almost ready for the market. Appropriate 3D bio-printers serially assemble the cultured cell strands into muscle tissue. In 2020, prices were around 8 to 10 euros per burger (about 140 grams). Today, a number of start-ups are striving to bring their products to market soon at competitive prices.
Farms are also significant virus spinners
Anyone who thinks that artificially produced in-vitro meat is not very appetizing or that a diet of artificially produced meat would take people too far away from nature should spend a few hours in a large slaughterhouse or watch a large agricultural producer.
In the summer of 2020 with the Tnnies crisis in Germany, we became involuntary witnesses of the terrible conditions of todays industrial meat production. The mass production of animals in todays large farms is hardly more appetizing.
Next to wild animals, farms are also significant virus spinners. And the monocultures of todays plant food production, including those for animal feed, are coming with such massive damage to nature (soil compaction, soil erosion, fertilizers and pesticides in the groundwater, bee deaths due to pesticides) that the call for an agricultural turnaround is becoming ever louder. Instead of being a step away from nature, artificial meat production is a powerful step for its protection, i.e. a step towards nature!
Diet becomes healthier without having to sacrifice taste
And as far as palatability is concerned, probably the most important criterion for what we eat, apart from health, the alternative meat producers work together with gourmet chefs and butchers, but also with food technicians, taste experts and manufacturers of flavors and fragrances to optimize juiciness, texture and mouthfeel. Their aim is to simulate the taste of the steak deceptively realistically and by adding appropriate flavors even improve it. First testers unanimously certify that the printed steaks taste like real meat, tasty, firm to the bite and fibrous like the original.
The food market is facing a revolution. Plant food stands up quite favorably in terms of climate balance, in contrast to meat from animal production. Meat and seafood grown from cells and printed by 3D printers will dramatically reduce industrial animal husbandry and even increase our gourmet pleasure. It is estimated that by 2040 35 percent of all meat will be produced in this way.
The popular German philosopher Richard David Precht already paints the picture of a society without livestock farming, but with meat that we print out ourselves instead of it coming from pasture. In this way, we ensure the nutrition of the growing world population and reduce the ecological footprint of our diet. At the same time, our diet becomes healthier without having to sacrifice taste.
Lars Jaeger is a Swiss-German author and investment manager. He writes on the history and philosophy of science and technology and has in the past been an author on hedge funds, quantitative investing, and risk management.
Previous contributions: Rudi Bogni, Peter Kurer, Rolf Banz, Dieter Ruloff, Werner Vogt, Walter Wittmann, Alfred Mettler, Robert Holzach, Craig Murray, David Zollinger, Arthur Bolliger, Beat Kappeler, Chris Rowe, Stefan Gerlach, Marc Lussy, Nuno Fernandes, Richard Egger, Maurice Pedergnana, Marco Bargel, Steve Hanke, Urs Schoettli, Ursula Finsterwald, Stefan Kreuzkamp, Oliver Bussmann, Michael Benz, Albert Steck, Martin Dahinden, Thomas Fedier, Alfred Mettler,Brigitte Strebel, Mirjam Staub-Bisang, Nicolas Roth, Thorsten Polleit, Kim Iskyan, Stephen Dover, Denise Kenyon-Rouvinez, Christian Dreyer, Kinan Khadam-Al-Jame, Robert Hemmi,Anton Affentranger,Yves Mirabaud, Katharina Bart, Frdric Papp, Hans-Martin Kraus, Gerard Guerdat, MarioBassi, Stephen Thariyan, Dan Steinbock, Rino Borini,Bert Flossbach, Michael Hasenstab, Guido Schilling, Werner E. Rutsch,Dorte Bech Vizard, Adriano B. Lucatelli, Katharina Bart, Maya Bhandari, Jean Tirole, Hans Jakob Roth,Marco Martinelli, Thomas Sutter,Tom King,Werner Peyer, Thomas Kupfer, Peter Kurer,Arturo Bris,Frederic Papp,James Syme, DennisLarsen, Bernd Kramer, Ralph Ebert, Armin Jans,Nicolas Roth, Hans Ulrich Jost, Patrick Hunger, Fabrizio Quirighetti,Claire Shaw, Peter Fanconi,Alex Wolf, Dan Steinbock, Patrick Scheurle, Sandro Occhilupo, Will Ballard, Michael Bornhaeusser, Nicholas Yeo, Claude-Alain Margelisch, Jean-Franois Hirschel, Jens Pongratz, Samuel Gerber, Philipp Weckherlin, Anne Richards, Antoni Trenchev, Benoit Barbereau, Pascal R. Bersier, Shaul Lifshitz, Klaus Breiner, Ana Botn, Martin Gilbert, Jesper Koll, Ingo Rauser, Carlo Capaul, Claude Baumann, Markus Winkler, Konrad Hummler, Thomas Steinemann, Christina Boeck, Guillaume Compeyron, Miro Zivkovic, Alexander F. Wagner, Eric Heymann, Christoph Sax, Felix Brem, Jochen Moebert, Jacques-Aurlien Marcireau, Ursula Finsterwald, Claudia Kraaz, Michel Longhini, Stefan Blum, Zsolt Kohalmi, Karin M. Klossek, Nicolas Ramelet, Sren Bjnness, Lamara von Albertini, Andreas Britt, Gilles Prince, Darren Willams, Salman Ahmed, Stephane Monier, and Peter van der Welle, Beat Wittmann, Ken Orchard, Christian Gast, Didier Saint-Georges, Jeffrey Bohn, Juergen Braunstein, Jeff Voegeli, Fiona Frick, Stefan Schneider, Matthias Hunn, Andreas Vetsch, Fabiana Fedeli, Marionna Wegenstein, Kim Fournais, Carole Millet, Ralph Ebert, Lars Jaeger, Swetha Ramachandran, Brigitte Kaps, Thomas Stucki, Teodoro Cocca, Neil Shearing, Claude Baumann, Guy de Blonay, Tom Naratil, Oliver Berger, Robert Sharps, Tobias Mueller, Florian Wicki, Jean Keller, Fabrizio Pagani, Niels Lan Doky, Michael Welti, Karin M. Klossek, Ralph Ebert, Johnny El Hachem, Judith Basad, Katharina Bart, Thorsten Polleit, Beat Wittmann,Bernardo Brunschwiler, Peter Schmid, Karam Hinduja, Stuart Dunbar, Zsolt Kohalmi, Lars Jaeger, Raphal Surber, Santosh Brivio, Grard Piasko, Mark Urquhart, Olivier Kessler, Bruno Capone, and Peter Hody.
Read more:
Lars Jaeger: The Future is Veggie, With 3D Printing - finews.asia
- Hannah just thought she was being clumsy, but her bruises were a sign she needed to see her doctor - Daily Mail - October 27th, 2023
- Brent Rutemiller's Cancer In Early Remission After 42 Weeks of Chemotherapy and Stem Cell Transplant - Swimming World Magazine - May 20th, 2022
- Other Notable Health Studies & Research From May 17, 2022 - Study Finds - May 20th, 2022
- Clinton County Relay For Life holds annual event in Riverview Park - Lock Haven Express - May 20th, 2022
- Illinois Is Being Invaded By Worms That Jump A Foot In The Air - 1440wrok.com - May 20th, 2022
- Moderna, J&J COVID Booster Shots Near Authorization. Here's What to Know - NBC Chicago - October 26th, 2021
- GenFleet Announces First Patient Dosed in Phase Ib/II Trial of TGF- R1 Inhibitor in Combination with PD-1 Inhibitor in Global Multi-center Research -... - October 26th, 2021
- Merck Provides Update on KEYTRUDA (pembrolizumab) Indication in Third-Line Gastric Cancer in the US - Business Wire - July 6th, 2021
- Orchard Therapeutics and Pharming Group Announce Collaboration to Develop and Commercialize ex vivo autologous HSC Gene - GlobeNewswire - July 6th, 2021
- New global guidelines for stem cell research aim to drive discussions, not lay down the law - The Conversation AU - May 27th, 2021
- Merck (MRK) Granted Positive EU CHMP Opinion for KEYTRUDA (pembrolizumab) in Combination with Chemotherapy - StreetInsider.com - May 27th, 2021
- Merck Receives Positive EU CHMP Opinion for KEYTRUDA in Combination With Chemotherapy as First-Line Treatment for Certain Patients With Esophageal... - May 27th, 2021
- Epigenetic therapies for heart failure | VHRM - Dove Medical Press - May 27th, 2021
- OPDIVO (nivolumab) in Combination with CABOMETYX (cabozantinib) Shows Sustained Survival and Response Rate Benefits as First-Line Treatment for... - February 14th, 2021
- AlloVir Research Presented at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience - Business Wire - February 14th, 2021
- Opdivo in Combination with Cabometyx Shows Sustained Survival and Response Rate Benefits as First-Line Treatment for Patients with Advanced RCC -... - February 14th, 2021
- Astellas and Seagen Announce Presentation of Results from PADCEV (enfortumab vedotin-ejfv) Pivotal Trial in Patients with Previously Treated Advanced... - February 14th, 2021
- [Full text] Loganin Attenuates Septic Acute Renal Injury with the Participation of | DDDT - Dove Medical Press - February 14th, 2021
- [Full text] Encephalopathy Induced by Preventive Administration of Acyclovir in a | IJGM - Dove Medical Press - February 14th, 2021
- Joint inflammation: Causes, treatment, and symptoms - Medical News Today - February 14th, 2021
- Creative Medical Technology Holdings Identifies and Files Patent on Novel Mechanism of ImmCelz Therapeutic Activity - PRNewswire - February 3rd, 2021
- How Coronavirus Damages Lung Cells Within Mere Hours And What Drugs Could Halt COVID-19 Infection - SciTechDaily - February 3rd, 2021
- Mini kidneys bioprinted in the lab - Lab + Life Scientist - December 4th, 2020
- Telix Pharmaceuticals Limited Acquires TheraPharm GmbH, Broadening Reach to Hematologic Cancers and Transplant Medicine - BioSpace - December 4th, 2020
- News briefing: Four biotechs announce IPO terms, setting the pace to round out a busy year; FDA sets PDUFA date for Kadmon's graft-versus-host drug -... - December 4th, 2020
- Government of Canada and JDRF Canada announce new research funding to accelerate stem cell-based therapies for type 1 diabetes - Philippine Canadian... - December 4th, 2020
- Merck Announces KEYNOTE-598 Trial Evaluating KEYTRUDA in Combination With Ipilimumab Versus KEYTRUDA Monotherapy in Certain Patients With Metastatic... - November 11th, 2020
- KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) Demonstrated Statistically Significant Improvement in Progression-Free Survival (PFS), Overall... - November 11th, 2020
- Gilead and Kite to Share Latest Scientific Advances in Hematologic Malignancies at ASH 2020 - Investing News Network - November 11th, 2020
- The great reset: new danger on the horizon - Amandala - November 11th, 2020
- Teladoc Is A Strong Buy: A Radical Healthcare Change Will Come - Seeking Alpha - November 11th, 2020
- COVID Drug Given to Trump Developed From Aborted Fetus Cells - Quint Fit - October 10th, 2020
- Laid off from ImmunoGen, an ex-Genzyme and Shire exec heads to an ARCH upstart - Endpoints News - October 10th, 2020
- 5 Deadly Pre-existing Conditions You Could Have Due To COVID-19 - Brumpost - Brumpost - October 10th, 2020
- The Crypto Daily Movers and Shakers October 10th, 2020 - Sports Grind Entertainment - October 10th, 2020
- Coronavirus Tracker: Bexar Co. cases surpass 59,000; Texas hospitalizations trending in the wrong direction - KENS5.com - October 10th, 2020
- Ligand Announces its Captisol Business is Positioned for Major Growth and Forecasts 2021 Captisol Material Sales of $200 Million - Business Wire - September 24th, 2020
- Seattle Genetics and Merck Announce Two Strategic Oncology Collaborations - BioSpace - September 15th, 2020
- Alexion and Caelum Biosciences Announce Start of Phase 3 Studies of CAEL-101 in AL Amyloidosis - Business Wire - September 15th, 2020
- Braunstein Reflects on the Rise of Quadruplet Therapies in Multiple Myeloma - OncLive - September 9th, 2020
- Roche receives FDA clearance for BK virus quantitative test on cobas 6800/8800 Systems to support better care for transplant patients - GlobeNewswire - September 9th, 2020
- ASX Biotechs Surfing The Covid Story - FN Arena News - August 16th, 2020
- Merck and Eisai Receive Complete Response Letter for KEYTRUDA (pembrolizumab) plus LENVIMA (lenvatinib) Combination as First-Line Treatment for... - July 10th, 2020
- FDA Approves Talaris Therapeutics' IND for Its Allogeneic Cell Therapy FCR001 to Be Evaluated in Patients With a Severe Form of Scleroderma - Business... - July 10th, 2020
- Coronavirus PPP Loans In Livingston: Where The Money Went - Livingston, NJ Patch - July 9th, 2020
- Stem Cell Therapy For Kidney Failure. Learn More Now ... - July 7th, 2020
- Anemia in chronic kidney disease - kidneyfund.org - July 7th, 2020
- Dr Borehams Crucible: Mesoblast within months of 3 major trial results, key regulatory decision - Stockhead - July 7th, 2020
- FDA Approves Merck's KEYTRUDA (pembrolizumab) for First-Line Treatment of Patients With Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer -... - June 30th, 2020
- R3 International Offering Stem Cell Therapy Program for Anti Aging in Mexico - PR Web - June 30th, 2020
- Vitro Bio-Pharma 2nd Quarter Ended April 30th 2020 Financial Results of Operations and Shareholder Letter - Stockhouse - June 30th, 2020
- FDA Approves Merck's KEYTRUDA (pembrolizumab) for the Treatment of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) that... - June 25th, 2020
- Simcha Therapeutics Launches to Engineer Therapeutic Cytokines to Unlock the Full Potential of the Immune System - Business Wire - June 25th, 2020
- First American to Receive Placental Cell Treatment For COVID-19 is an Acclaimed Broadway Scenic Designer - Science Times - May 27th, 2020
- Scientists generate millions of mature human cells, far more than have ever been produced - UB News Center - May 20th, 2020
- Heres The Reason Why Scientists Are Growing Human Cells In Mouse Embryo - Medical Daily - May 20th, 2020
- Cell therapies trial planned for COVID-19 - Mirage News - May 5th, 2020
- New Study Finds That Wearing Contact Lenses Doesn't Increase Risk of COVID-19 Infection - HealthDay Coronavirus Liveblog - April 26th, 2020
- Israeli COVID-19 treatment with 100% survival rate tested on US patient - The Jerusalem Post - April 15th, 2020
- Stem Cells and Chronic Kidney Disease | Mayo Clinic Center ... - April 11th, 2020
- Kidney Failure | Stem Cell Treatment in Tijuana Mexico - April 11th, 2020
- MESOBLAST PARTNERS WITH THE CARDIOTHORACIC SURGICAL TRIALS NETWORK ESTABLISHED BY THE U.S. NATIONAL INSTITUTES OF HEALTHS NATIONAL HEART, LUNG AND... - April 11th, 2020
- Merck Receives Priority Review from FDA for Second Application for KEYTRUDA (pembrolizumab) Based on Biomarker, Regardless of Tumor Type - Benzinga - April 11th, 2020
- A coronavirus vaccine is being developed in record time. But dont expect that technology to speed up flu vaccines yet. - Columbia Daily Herald - April 7th, 2020
- Researchers test drug that stops early stages of COVID-19 - Open Access Government - April 7th, 2020
- Can cell-based therapy be helpful in tackling coronavirus? - YourStory - March 25th, 2020
- Made-in-space organs could soon be reality - ETHealthworld.com - March 13th, 2020
- What Is the Coronavirus? - WIRED - March 6th, 2020
- 34 years with a new heart and counting - MDJOnline.com - February 25th, 2020
- Coronavirus: Doctors try 3,000-year-old Traditional Chinese Medicine (TCM) to treat the virus - Times of India - February 20th, 2020
- Merck's KEYTRUDA (pembrolizumab) in Combination with Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Treatment for... - February 14th, 2020
- Seattle Genetics and Astellas Announce Updated Results from Phase 1b/2 Trial of PADCEV (enfortumab vedotin-ejfv) in Combination with Immune Therapy... - February 14th, 2020
- Omeros: 2 Major Catalysts On The Horizon - Seeking Alpha - February 10th, 2020
- Cambridge Science Festival showcases new research at the forefront of healthcare and medicine - Cambridge Network - February 10th, 2020
- Anemia: Causes, symptoms and treatment - Livescience.com - February 8th, 2020
- 4 Crazy but Effective Ways to Save More Money This Year - Nasdaq - February 4th, 2020
- BAME lives to be saved as new organ donation law rolls out - Keep the Faith - January 15th, 2020
- HIV drug resistance an emerging threat, expert warns - DAWN.com - January 10th, 2020
- A Lasting Legacy: DuPont, C8 Contamination and the Community Left to Grapple With the Consequences - alleghenyfront.org - January 10th, 2020
- Merck's KEYTRUDA (pembrolizumab) in Combination with Chemotherapy Significantly Improved Progression-Free Survival Compared to Chemotherapy Alone as... - January 6th, 2020